Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma.

ABSTRACT:

Background

Cabozantinib combined with atezolizumab has been shown to prolong progression-free survival in first-line treatment of advanced hepatocellular carcinoma (HCC). However, the cost-effectiveness of this regimen remains unknown. This study aimed to evaluate the cost-effectiveness of cabozantinib plus atezolizumab compared with sorafenib for first-line treatment of advanced HCC from the perspectives of the Chinese health system and the US payers.

Methods

A partitioned survival model was constructed based on a phase III randomized clinical trial (COSMIC-312) to compare the health benefits and economic outcomes of cabozantinib plus atezolizumab versus sorafenib for the treatment of hepatocellular carcinoma. Costs and utilities were obtained from published literature. Dat

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC12545015 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature